本帖最后由 老马 于 2012-1-13 21:20 编辑 0 S0 h+ z0 x/ r! }. G H1 m
; `# k$ m; M( V6 L Q3 |0 X
爱必妥和阿瓦斯丁的比较
; ?: u! D; @$ J& d9 k* [
- M# a4 ~ W1 Q. F0 l% ]http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 F1 s6 c3 D/ }2 j
" a |9 e7 ]% A6 s
7 M; Z- k0 d o' Q) T
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ Y9 g& B U! O; ?+ D1 p4 w- v
==================================================
) e6 c% d' u) Q' X0 f2 COverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 M& @$ R4 f- x7 P
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- m( y$ t$ b( pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.1 ?0 m& ]+ J' r- N
|
11011102001537 )
显身卡
